Treatment Guidelines - Issue 123 | The Medical Letter Inc.

Treatment Guidelines from The Medical Letter

FROM
ISSUE

123

November 1, 2012

View Complete Issue Table of Contents 2019

Issue 123

Drugs for Some Common Eye Disorders

Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.

Drugs for Some Common Eye Disorders

November 1, 2012 (Issue: 123)

Drugs for glaucoma, age-related macular degeneration, bacterial conjunctivitis, and dry eyes are reviewed here. Drugs for the treatment of allergic conjunctivitis will be reviewed in a future issue of Treatment Guidelines on Drugs for Allergic...more

Show References Hide References

1. Tafluprost (Zioptan) - a new topical prostaglandin for glaucoma. Med Lett Drugs Ther 2012; 54:31.

2. K Inoue et al. Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs. J Glaucoma 2012; August 29 (epub).

3. JH Liu et al. Diurnal and nocturnal effects of brimonidine monotherapy on intraocular pressure. Ophthalmology 2010; 117:2075.

4. S Arthur and LB Cantor. Update on the role of alpha-agonists in glaucoma management. Exp Eye Res 2011; 93:271.

5. RJ Casson et al. Efficacy and safety of bimatoprost as replacement for latanoprost in patients with glaucoma or ocular hypertension: a uniocular switch study. J Glaucoma 2009; 18:582.

6. LP Aiello. Targeting intraocular neovascularization and edema – one drop at a time. N Engl J Med 2008; 359:967.

7. Pegaptanib sodium (Macugen) for macular degeneration. Med Lett Drugs Ther 2005; 47:55.

8. Ranibizumab (Lucentis) for macular degeneration. Med Lett Drugs Ther 2006; 48:85.

9. PJ Rosenfeld et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1419.

10. CD Regillo et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008; 145:239.

11. BA Frost and MA Kainer. Safe preparation and administration of intravitreal bevacizumab injections. N Engl J Med 2011; 365:2238.

12. CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364:1897.

13. CATT Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012; 119:1388.

14. Aflibercept (Eylea) for age-related macular degeneration. Med Lett Drugs Ther 2012; 54:9.

15. S Day et al. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. Am J Ophthalmol 2011; 152:266.

16. FG Holz et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011; 118:663.

17. Photodynamic therapy with verteporfin (Visudyne) for macular degeneration. Med Lett Drugs Ther 2000; 42:81.

18. NM Bressler. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) study group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001; 119:198.

19. M Azab et al. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005; 123:448.

20. JB Jonas et al. Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative non-randomized study. Eye (Lond) 2005; 19:163.

22. Nutritional support for macular degeneration. Med Lett Drugs Ther 2010; 52:63.

23. The ATBC Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994; 330:1029.

24. GS Omenn et al. Effects of a combination of beta carotene and vitamin Aon lung cancer and cardiovascular disease. N Engl J Med 1996; 334:1150.

25. ER Miller 3rd et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142:37.

26. I Bairati et al. Antioxidant vitamins supplementation and mortality: a randomized trial in head and neck cancer patients. Int J Cancer 2006; 119:2221.

27. W Haas et al. Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile. Clin Ophthalmol 2011; 5:1369.

28. Opthalmic azithromycin (AzaSite). Med Lett Drugs Ther 2008; 50:11.

29. Ophthalmic Besifloxacin (Besivance). Med Lett Drugs Ther 2009; 51:101.

30. WB Jackson. Management of dysfunctional tear syndrome: a Canadian consensus. Can J Ophthalmol 2009; 44:385.

31. AH Wander and BH Koffler. Extending the duration of tear film protection in dry eye syndrome: review and retrospective case series study of the hydroxypropyl cellulose ophthalmic insert. Ocul Surf 2009; 7:154.

32. Ophthalmic cyclosporine (Restasis) for dry eye disease. Med Lett Drug Ther 2003; 45:42.

33. HD Perry et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol 2008; 126:1046.

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.